金斯瑞生物科技(01548.HK):傳奇生物審閲最新CARTITUDE-1數據的投資者KOL虛擬活動
格隆匯11月24日丨金斯瑞生物科技(01548.HK)公佈,公司非全資附屬公司傳奇生物科技股份有限公司已向美國證券交易委員會提交6-K表格,內容有關於美國東部時間2020年12月7日下午七時正舉行的關鍵意見領袖(KOL)虛擬活動,強調來自西達基奧侖賽(cilta-cel)(一種在研BCMA靶向CAR-T細胞療法,正在研究用於治療復發或難治性多發性骨髓瘤患者)1b/2期CARTITUDE-1研究(NCT03548207)的最新數據。該活動於最近於第62屆美國血液學會(ASH)年會上有關研究結果(摘要#177)的口頭陳述後進行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.